Warburg Research Analysts Give Fresenius SE & Co KGaA (FRE) a €77.00 Price Target

Warburg Research set a €77.00 ($89.53) price target on Fresenius SE & Co KGaA (FRA:FRE) in a report released on Tuesday morning. The brokerage currently has a buy rating on the stock.

A number of other research firms have also recently issued reports on FRE. UBS Group set a €57.00 ($66.28) price objective on shares of Fresenius SE & Co KGaA and gave the stock a sell rating in a research report on Monday, August 6th. DZ Bank restated a buy rating on shares of Fresenius SE & Co KGaA in a report on Tuesday, August 7th. Deutsche Bank set a €82.00 ($95.35) target price on shares of Fresenius SE & Co KGaA and gave the stock a buy rating in a report on Thursday, July 19th. Sanford C. Bernstein set a €83.00 ($96.51) target price on shares of Fresenius SE & Co KGaA and gave the stock a buy rating in a report on Monday, July 9th. Finally, Independent Research set a €80.00 ($93.02) target price on shares of Fresenius SE & Co KGaA and gave the stock a buy rating in a report on Tuesday, October 2nd. One investment analyst has rated the stock with a sell rating, six have assigned a hold rating and fourteen have issued a buy rating to the stock. Fresenius SE & Co KGaA currently has an average rating of Buy and a consensus price target of €75.94 ($88.31).

FRE stock opened at €56.58 ($65.79) on Tuesday. Fresenius SE & Co KGaA has a 1 year low of €60.16 ($69.95) and a 1 year high of €80.00 ($93.02).

About Fresenius SE & Co KGaA

Fresenius SE & Co KGaA, a health care group, provides products and services for dialysis, hospitals, and outpatient medical care worldwide. The company operates through Fresenius Medical Care, Fresenius Kabi, Fresenius Helios, and Fresenius Vamed segments. The Fresenius Medical Care segment offers products for patients with chronic kidney failure.

See Also: Earnings Reports

Analyst Recommendations for Fresenius SE & Co KGaA (FRA:FRE)

Receive News & Ratings for Fresenius SE & Co KGaA Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Fresenius SE & Co KGaA and related companies with MarketBeat.com's FREE daily email newsletter.


Leave a Reply